Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Other Non Operating Income (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Other Non Operating Income over the past 3 years, most recently at -$1.2 million for Q4 2025.

  • Quarterly results put Other Non Operating Income at -$1.2 million for Q4 2025, down 303.21% from a year ago — trailing twelve months through Dec 2025 was -$3.3 million (down 406.14% YoY), and the annual figure for FY2025 was -$3.3 million, changed.
  • Other Non Operating Income for Q4 2025 was -$1.2 million at Tonix Pharmaceuticals Holding, up from -$2.1 million in the prior quarter.
  • Over the last five years, Other Non Operating Income for TNXP hit a ceiling of $897000.0 in Q1 2023 and a floor of -$2.1 million in Q1 2025.
  • Median Other Non Operating Income over the past 3 years was -$18500.0 (2023), compared with a mean of -$222400.0.
  • Biggest five-year swings in Other Non Operating Income: surged 8357.14% in 2024 and later tumbled 303.21% in 2025.
  • Tonix Pharmaceuticals Holding's Other Non Operating Income stood at $7000.0 in 2023, then surged by 8357.14% to $592000.0 in 2024, then tumbled by 303.21% to -$1.2 million in 2025.
  • The last three reported values for Other Non Operating Income were -$1.2 million (Q4 2025), -$2.1 million (Q1 2025), and $592000.0 (Q4 2024) per Business Quant data.